Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4825-4833

  Staff, Anne Cathrine ^a,b   Trovik, Jone ^c,d   Eriksson, Ane Gerda Zahl ^a   Wik, Elisabeth ^d   Wollert, Kai C ^e   Kempf, Tibor ^e   Salvesen, Helga B ^c,d  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960390271     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0715     Document Type: Article

References (40)

1. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, et al. Stathmin overexpression identifies high risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011;17:3368-77.
2. Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, et al. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol Oncol 2009;3:491-5.
3. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;5:1382-90. (Pubitemid 29220843)
4. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;1:24-38. (Pubitemid 38117046)
5. Kaku T, Kamura T, Hirakawa T, Sakai K, Amada S, Kobayashi H, et al. Endometrial carcinoma associated with hyperplasia-immunohistochemical study of angiogenesis and p53 expression. Gynecol Oncol 1999;1:51-5. (Pubitemid 29045446)
6. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS 2009;10:693-707.
7. Amant F, Moerman P, Neven P, Timmerman D, Van LE, Vergote I. Endometrial cancer. Lancet 2005;9484:491-505. (Pubitemid 41111699)
8. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009;12:4834-9.
9. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 2010;3:237-43.
10. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;16:5034-40. (Pubitemid 37022642)
11. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;1:89-96. (Pubitemid 43166181)
12. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;7:2386-92. (Pubitemid 38445697)
13. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 2003;7:1101-4. (Pubitemid 36560783)
14. de Wit NJ, Rijntjes J, Diepstra JH, Van Kuppevelt TH, Weidle UH, Ruiter DJ, et al. Analysis of differential gene expression in human melanocytic tumor lesions by custommade oligonucleotide arrays. Br J Cancer 2005;12:2249-61. (Pubitemid 40966264)
15. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997;21:11514-9. (Pubitemid 27451030)
16. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;8:962-71. (Pubitemid 46328289)
17. Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007;23:2858-65. (Pubitemid 350233034)
18. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation 2010;14:1387-95.
19. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002;9324:2159-63. (Pubitemid 34694024)
20. Lawton LN, Bonaldo MF, Jelenc PC, Qiu L, Baumes SA, Marcelino RA, et al. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene 1997;1:17-26. (Pubitemid 27520649)
21. Sugulle M, Dechend R, Herse F, Weedon-Fekjaer MS, Johnsen GM, Brosnihan KB, et al. Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus.Hypertension 2009;1:106-12.
22. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;6:3410-5. (Pubitemid 36356597)
23. Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999;1:2-5. (Pubitemid 29024911)
24. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005;6:543-8. (Pubitemid 40677428)
25. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S, et al. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998;22:13760-7. (Pubitemid 28268424)
26. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006;10:4983-6. (Pubitemid 43852864)
27. Odegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, et al. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 2008;198:418e1-7.
28. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007;2:284-91. (Pubitemid 46338273)
29. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010;6:1057-64.
30. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006;11:1622-31. (Pubitemid 44666730)
31. Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR, Agarwal ML. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci U S A 2006;44:16278-83. (Pubitemid 44715187)
32. Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000;1:109-14. (Pubitemid 30055792)
33. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, et al. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000;26:20127-35. (Pubitemid 30441624)
34. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010;3:626-35.
35. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;7:2642-50. (Pubitemid 36842108)
36. Bock AJ, Stavnes HT, Berner AA, Wollert KC, Kempf T, Trope CG, et al. Expression and clinical role of growth differentiation factor-15 (GDF-15) in ovarian carcinoma effusions. Int J Gynecol Cancer 2010;20:1448-56.
37. Robison K, Holman LL, Moore RG. Update on sentinel lymph node evaluation in gynecologic malignancies. Curr Opin Obstet Gynecol 2011;1:8-12.
38. Benedetti PP, Basile S, Maneschi F, Alberto LA, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;23:1707-16.
39. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;9658:125-36.
40. Lee JY, Jung DC, Park SH, Lim MC, Seo SS, Park SY, et al. Pre-operative prediction model of lymph node metastasis in endometrial cancer. Int J Gynecol Cancer 2010;8:1350-5.